DHR vs TMO
Danaher Corporation and Thermo Fisher Scientific, both Healthcare
Thermo Fisher Scientific is the larger company at $173B against $125B. On trailing earnings TMO is the cheaper of the two at a P/E of 35.4 against 39.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year TMO returned +37% against +13% for DHR. The RyuScore puts DHR ahead, 51 against 50 out of 100.
| Figure | DHR | TMO |
|---|---|---|
| Last close | $220 | $658 |
| Market cap | $125B | $173B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 39.0 | 35.4 |
| Dividend yield | n/a | 0.3% |
| 1-year return | +13% | +37% |
| 5-year return | -21% | +19% |
| RyuScoresector-relative, 1–10 | 51/100 | 50/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Danaher Corporation
Revenue of $6.3B in Q2 2026, net income $870M. Its largest reported line is Diagnostics, 46% of the disclosed total.
Thermo Fisher Scientific
Revenue of $12B in Q2 2026, net income $1.7B. Its largest reported line is Life Sciences Solutions, 38% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.